# A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

> **NCT01174160** · PHASE3 · COMPLETED · sponsor: **Advanz Pharma** · enrollment: 123 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** vernakalant hydrochloride
- **DRUG:** Placebo to vernakalent hydrochloride

## Key facts

- **NCT ID:** NCT01174160
- **Lead sponsor:** Advanz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01174160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01174160, "A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01174160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*